An observational study in Tumor, Radiotherapy and Biomarker, sponsored by Nanfang Hospital, Southern Medical University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significantly elevated in patients with radioresistant tumors and may serve as a predictive biomarker for radiotherapy sensitivity. This study aims to conduct a multicenter, bidirectional cohort study to systematically evaluate the predictive value of peripheral blood CHI3L1 as a pan-cancer biomarker for tumor response to radiotherapy.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 338 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with tumors who require radiotherapy
Exclusion Criteria:
Objective Response Rate（ORR）
Objective Response Rate (ORR) after Radiotherapy in Tumor Patients
Time frame: Through study completion, up to 3 years
Local Control Rate
Local Control Rate after Radiotherapy in Tumor Patients
Time frame: Through study completion, up to 3 years
Local Relapse Free Survival
Locoregional Recurrence-Free Survival after Radiotherapy in Tumor Patients
Time frame: Through study completion, up to 3 years
Progression Free Survival
Progression-Free Survival after Radiotherapy in Tumor Patients
Time frame: Through study completion, up to 3 years
Overall Survival
Overall Survival after Radiotherapy in Tumor Patients
Time frame: Through study completion, up to 3 years
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University